louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT00709709: Medical Evaluation of Scanner in Coronary Syndrome
Official title: Medical and Economic Medical Evaluation of Scan Multislice of Coronary Artery in Exploration of Stable Coronary Syndrome. Comparison With Quantitative Coronarography
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Coronary Syndrome
Keywords: stenosis
coronaropathy
stent
bypass surgery
suspect
known
Lead sponsor: Assistance Publique - Hôpitaux de Paris
Sponsor class: OTHER
First posted: 2008-07-03
Enrollment: 1500
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: Many recent publications have reported encouraging results on diagnostic cardiac multislice CT performance in 1) coronary artery disease, 2) coronary arterial bypass graft potency and 3) intrastent restenosis.

These single center studies were made on a limited number of patients (range, 50-130) and focused mainly on one of the indications mentioned above.

Moreover, results were often given after exclusion of low quality examinations. At last, no study has compared the diagnostic performance of the different CT systems '16, 40 and 64) in these populations.

Detailed description: These single center studies were made on a limited number of patients (range, 50-130) and focused mainly on one of the indications mentioned above.

Moreover, results were often given after exclusion of low quality examinations. At last, no study has compared the diagnostic performance of the different CT systems '16, 40 and 64) in these populations.

Eligibility criteria: Inclusion Criteria:

* Patients' ≥18 years, of both sexes
* Coronary angiography in patients with suspected of known CAD, instable clinical conditions.
* Clinical status allowing performance of coronary angiography 48 à 72h after CT examination
* Informed consent signed by patient

Exclusion Criteria:

* Patients in whom clinical status does not allow delayed coronary angiography
* Irregular heart rate, in particular atrial fibrillation
* Renal insufficiency (serum creatinine \>150 µmol/l
* Radiology examination with use of iodin agent with 48h before) CT coronary
* K now intolerance to iodin agents
* Patients unable to hold breathing \< 20 seconds
* Pregnancy

Primary outcomes:
measure: Specificity and sensibility of scanner
timeFrame: visit 1
Secondary outcomes:
measure: Quality of coronary scanner imaging
timeFrame: visit 1
Other outcomes:
Locations:
city: Creteil
country: France
facility: CHU Henri Mondor
Study officials:
affiliation: Assistance Publique - Hôpitaux de Paris
name: Pascal Gueret, PUPH
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04080609: DDI Study Between Dorzagliatin and Rifampicin
Official title: A Single Dose, Open Label, Drug-drug Interaction Study to Investigate the Pharmacokinetics and Safety of Dorzagliation Administered Alone or in Combination With Rifampicin in Healthy Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Drug Interaction
Lead sponsor: Hua Medicine Limited
Sponsor class: INDUSTRY
First posted: 2019-09-06
Enrollment: 15
Sex: ALL
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Intervention model: SEQUENTIAL
Primary purpose: TREATMENT

Brief summary: The purpose of this drug-drug interaction study is to investigate the impact of rifampicin on the pharmacokinetics of Dorzagliatin.


Eligibility criteria: Inclusion Criteria:

* Body weight ≥ 50 kg (male) or ≥ 45 kg (female)
* BMI within 19～26 kg/m2

Exclusion Criteria:

* History or disease status that may impact the ADME of the study
* Use of any drugs, OTCs, or hebal within 4 weeks of screening
* Drug abuse
* Blood donation

Primary outcomes:
measure: Cmax
timeFrame: up to 96 hours
measure: AUClast
timeFrame: up to 96 hours
Secondary outcomes:
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Central Hospital of Xuhui District
state: Shanghai
Study officials:
References:
Clinical trial NCT03086109: The Prevalence of Bone Degenerative Diseases in Beijing - a Cross-sectional Study
Official title: The Prevalence of Bone Degenerative Diseases in Beijing - a Cross-sectional Study
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Cross-sectional Study
Degenerative Disease Joint
Degenerative Disc Disease
Keywords: prevalence
Bone Degenerative Disease
Lead sponsor: Beijing Jishuitan Hospital
Sponsor class: OTHER
First posted: 2017-03-22
Enrollment: 850
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: ECOLOGIC_OR_COMMUNITY
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The residents of Beijing voluntary to participant to this study

Brief summary: The purpose of this observational study is to investigate the prevalence and risk factors of bone degenerative diseases


Eligibility criteria: Inclusion Criteria:

1. Aged 18-65 years， residents of Beijing city
2. Must demonstrate willingness to participate in the study by signing the written informed consent

Exclusion Criteria:

1. Subjects who had surgery on disc or knee
2. Pregnent women

Primary outcomes:
measure: Prevalence of bone degenerative diseases
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Beijing
country: China
facility: Beijing Jishuitan Hospital
Study officials:
affiliation: Beijing Jishuitan Hospital
name: Wei Tian, MD
role: STUDY_DIRECTOR
References:
Clinical trial NCT05881109: Population Pharmacokinetics and Dose Optimization of Caspofungin in Adolescents
Official title: Population Pharmacokinetics and Dose Optimization of Caspofungin in Adolescents With Allogeneic Hematopoietic Stem Cell Transplantation
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Invasive Fungal Infections
Lead sponsor: Shandong University
Sponsor class: OTHER
First posted: 2023-05-31
Enrollment: 30
Sex: ALL
Minimum age (years): 12
Maximum age (years): 17
Standard ages: CHILD
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: The adolescents (12 - 17 years old) undergoing allo-HSCT and receiving CAS as prevention or treatment for IFIs

Brief summary: Caspofungin (CAS) is used to prevent and treat invasive fungal infections patients older than 3 months. However, the optimal dosing strategy of CAS is lacking in adolescents from 12 to 17 years old, especially those undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT), who are vulnertable to fungal infections. The study aimed to establish a population pharmacokinetic (PPK) model and assess the dosing schemes of CAS in adolescents with allogeneic hematopoietic stem cell transplantation (allo-HSCT).


Eligibility criteria: Inclusion Criteria:

* The adolescents (12 - 17 years) underwent allo-HSCT
* Use caspofungin for the prevention or treatment of fungal infections

Exclusion Criteria:

* Intolerable to caspofungin
* Participate into other clinical studies
* There are conditions that researchers do not consider it appropriate to join the research.

Primary outcomes:
measure: The PTAs of AUC24/MIC90 for C. albicans , C. glabrata , and C. parapsilosis
timeFrame: 1 day
measure: The PTAs of AUC24/MIC for various species of Candida spp isolates
timeFrame: 1 day
measure: The PTAs of trough concentration
timeFrame: the trough concentration (24 hours after administration) at the steady state
Secondary outcomes:
Other outcomes:
Locations:
city: Wuhan
country: China
facility: Wuhan Children's Hospital
Study officials:
References:
Clinical trial NCT03286309: Soft Robotic Hand System for Stroke Rehabilitation
Official title: Soft Robotic Hand System for Stroke Rehabilitation
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Stroke
Lead sponsor: Chinese University of Hong Kong
Sponsor class: OTHER
First posted: 2017-09-18
Enrollment: 40
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The soft robotic system could provide objective and quantifiable measures of subject performance. By combining voluntary motor intention and the robotic hand technology, the system will facilitate the recovery process of stroke patients.


Eligibility criteria: Inclusion criteria:

1. at chronic stage (6 months after the onset of stroke) with a pure unilateral motor paresis after a stroke (ischemic or hemorrhagic);
2. sufficient cognition to follow simple instructions as well as understand the content and purpose of the study;
3. able to sit up for 45 minutes (with or without assistance).

Exclusion criteria:

1. Patients with severe dysphasia (either expressive or comprehensive) with inadequate communication;
2. any additional medical or psychological condition affecting their ability to comply with the study protocol;
3. history of other neurological disease, psychiatric disorder, including alcoholism and substance abuse.

Primary outcomes:
measure: Upper limb Fugl Meyer Assessment
timeFrame: 3-month follow up
Secondary outcomes:
measure: Action Research Arm Test
timeFrame: 3-month follow up
measure: Modified Ashworth Scale
timeFrame: 3-month follow up
measure: Box and Block Test
timeFrame: 3-month follow up
measure: Max Voluntary Grip Force
timeFrame: 3-month follow up
Other outcomes:
Locations:
city: Shatin
country: Hong Kong
facility: Department of Biomedical Engineering, The Chinese University of Hong Kong
Study officials:
affiliation: Department of Biomedical Engineering, CUHK
name: Raymond Kai-yu Tong, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00647309: Troponin Elevation in the Elderly Patient With Hip Fracture
Official title: Correlation Between Troponin Level and Rehabilitation Outcome in Elderly Patient With Hip Fracture
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Hip Fracture
Lead sponsor: Sheba Medical Center
Sponsor class: OTHER_GOV
First posted: 2008-03-31
Enrollment: 100
Sex: ALL
Minimum age (years): 65
Standard ages: OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: patients aged 65 years and over with hip fracture

Brief summary: Elevated troponin is powerful and independent adverse prognostic marker in patient with ACS. However, non specific (non cardiac) troponin elevation is a common finding among hospitalized patients and worse prognosis too.

The aim of this study is examine the prevalence of incidental cardiac troponin rise in a group of patient aged 65 and over admitted to geriatric department with hip fracture, and influence of troponin elevation on outcomes like ACS, death, motor and cognitive function.

Detailed description: data collection will include epidemiological data (age, gender, living arrangement, basic functional status, fracture date, surgery date, surgery type, length of stay) as well as previous comorbidities. in addition, routine blood tests and baseline ECG will be recorded.

troponin levels will be studied within 24 hours from admission, and 24 hours following surgery. in case of elevated troponin levels, ECG will be repeated, and echocardiography together with a cardiologist evaluation will be carried out.

data regarding in-hospital complications, motor and cognitive function (by FIM scale) and lab will be recorded. after discharge. followup will be recorded every 3 months, up to 1 year period, recoding the above mentioned data.

Eligibility criteria: Inclusion Criteria:

* Age 65 and over with hip fracture

Exclusion Criteria:

* None

Primary outcomes:
measure: all cause mortality, motor and cognitive function
timeFrame: one year
Secondary outcomes:
Other outcomes:
Locations:
city: Ramat Gan
country: Israel
facility: Sheba Medical Center, Geriatric Rehabilitation dept
Study officials:
affiliation: Sheba Medical Center
name: Marina Arad, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05517109: Hemodynamic in Postreperfusion Period and Functional Recovery in Acute Ischemic Stroke Patients
Official title: The Influence of Different Hemodynamic Parameters in First 24 Hours After Intravenous Thrombolysis on Acute Ischemic Stroke Outcomes: a Randomised Clinical Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Acute Ischemic Stroke
Intracranial Hemorrhage
Lead sponsor: Northern State Medical University
Sponsor class: OTHER
First posted: 2022-08-26
Enrollment: 90
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The investigators are suggtesting that lower goals of systolic blood pressure after intravenous thrombolysis may reduce the risk of hemorrhagic complications and improve functional outcomes after acute ischemic stroke.


Eligibility criteria: Inclusion сriteria:

* ischemic stroke diagnosis
* performed intravenous thrombolysis (including "wake up stroke")
* systolic blood pressure \>140 mmHg
* informed consent or council of physician agreement

Exclusion criteria:

* absence of informed consent or council of physician agreement
* pregnancy
* patients participainting in other clinical trial in the last 90 days
* any absolute contraindications to intravenous thrombolysis

Сompletion criteria:

* failure to achieve hemodynamic goal for 20 minutes before the start of intravenous thrombolysis
* failure to achieve hemodynamic goal for 60 minutes in first 24 hours after intravenous thrombolysis
* relative arterial hypotension (SBP \<100 mmHg for 60 minutes in first 24 hours after intravenous thrombolysis)
* unfavorable effect development (e.g. seizures, angioedema)
* informed consent is retracted

Primary outcomes:
measure: Modified Rankin Scale score
timeFrame: 90 day after intravenous thrombolysis
measure: Mortality rate
timeFrame: At 90 day after intravenous thrombolysis
measure: Rate of symptomatic intracranial hemorrhage
timeFrame: 24 hours after intravenous thrombolysis
measure: Rate of symptomatic intracranial hemorrhage
timeFrame: 7 days after intravenous thrombolysis
Secondary outcomes:
measure: Change in National Institutes of Health Stroke Scale (NIHSS)
timeFrame: at 28 day after intravenous thrombolysis
measure: Rate of all Intracranial hemorrhage
timeFrame: 24 hours after intravenous thrombolysis
measure: Rate of all Intracranial hemorrhage
timeFrame: 7 days after intravenous thrombolysis
measure: Lengths of stay in ICU
timeFrame: at 90 day after intravenous thrombolysis
measure: Lengths of stay in hospital
timeFrame: at 90 day after intravenous thrombolysis
measure: Rate of acute kidney injury
timeFrame: 28 day after intravenous thrombolysis or at discharge
Other outcomes:
Locations:
city: Arkhangelsk
country: Russian Federation
facility: City Hospital # 1 n.a. E.E. Volosevich
Study officials:
affiliation: Northen state medical university
name: Mikhail Kirov, PhD
role: STUDY_DIRECTOR
affiliation: Northen state medical university
name: Alexey Avidzba
role: STUDY_CHAIR
References:
Clinical trial NCT06145009: Time Restricted Eating, Eating Behaviors, and Cardiometabolic Risk in Emerging Adult Women
Official title: Time Restricted Eating, Eating Behaviors, and Cardiometabolic Risk in Emerging Adult Women
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Time Restricted Eating
Eating Behavior
Diet, Healthy
Nutrition, Healthy
Lead sponsor: University of Delaware
Sponsor class: OTHER
First posted: 2023-11-22
Enrollment: 36
Sex: ALL
Minimum age (years): 20
Maximum age (years): 29
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: The purpose of this study is to assess how time restricted eating interventions impact eating behaviors, diet quality, and body composition in women ages 20-29 years. Participants will be asked to limit all food and drinks (except water and some non-caloric beverages) to a 10-hour period during the day for four weeks. Participants will follow their usual eating and activity patterns for one week before starting, and follow whatever eating pattern they want for 4 weeks after finishing.


Eligibility criteria: Inclusion Criteria:

* Able to speak and read English
* Own a smartphone
* BMI ≥ 20 kg/m2
* Usual eating window ≥ 12 hours with the last eating occasion after 8pm on the majority of days
* Have at least a moderate baseline level of dietary restraint

Exclusion Criteria:

* Shift workers
* Being pregnant, nursing, or planning to become pregnant in the next 6 months
* Having a past or current eating disorder diagnosis
* Having a chronic medical condition (including diabetes, heart, kidney, or thyroid disease) or a condition that requires therapeutic diet or specified meal timing

Primary outcomes:
measure: Emotional Eating
timeFrame: 3 time points: baseline, end of 4-week intervention, end of 4-week follow up
measure: External Eating
timeFrame: 3 time points: baseline, end of 4-week intervention, end of 4-week follow up
measure: Eating in the Absence of Hunger
timeFrame: Baseline week, weeks 1 and 4 of intervention, weeks 1 and 4 of follow up
Secondary outcomes:
measure: Diet Quality
timeFrame: 3 time points: baseline, end of 4-week intervention, end of 4-week follow up
measure: Body composition (total percent body fat)
timeFrame: Baseline and end of 4-week intervention
measure: Body composition (visceral fat)
timeFrame: Baseline and end of 4-week intervention
measure: Body weight
timeFrame: 3 time points: baseline, end of 4-week intervention, end of 4-week follow up
Other outcomes:
measure: Participant experience
timeFrame: End of 9-week study (following 1-week baseline, 4-week intervention, and 4-week follow up)
Locations:
city: Newark
country: United States
facility: University of Delaware
state: Delaware
Study officials:
affiliation: University of Delaware
name: Carly Pacanowski, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01821456: Cologne Cohort of Neutropenic Patients (CoCoNut)
Official title: The Cologne Cohort of Neutropenic Patients (CoCoNut) - a Non-interventional Cohort Study Assessing Risk Factors, Interventions, and Outcome of Immunosuppressed Patients With or Without Opportunistic Infections
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Hematological Malignancies
Cancer
Chemotherapy
Neutropenia
Immunosuppression
Keywords: hematological malignancies
cancer
chemotherapy
anti-infectives
treatment
outcome
Lead sponsor: University Hospital of Cologne
Sponsor class: OTHER
First posted: 2013-04-01
Enrollment: 100000
Sex: ALL
Minimum age (years): 1
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All patients developing neutropenia after receiving chemotherapy for any kind of malignant disease, treated in the University Hospital of Cologne

Brief summary: The Cologne Cohort of Neutropenic Patients (CoCoNut) is a non-interventional cohort study assessing risk factors, interventions, and outcome of immunosuppressed patients with or without opportunistic infections.

Detailed description: This prospective cohort was established with the aim of a comprehensive data collection of all patients developing neutropenia after receiving chemotherapy for any kind of malignant disease, treated in the University Hospital of Cologne.

Eligibility criteria: Inclusion Criteria:

* immunosuppressed patients

Exclusion Criteria:

* none

Primary outcomes:
measure: Long-term survival of hematology and oncology patients following neutropenia
timeFrame: 2 years following last follow-up
Secondary outcomes:
Other outcomes:
Locations:
city: Cologne
country: Germany
facility: University Hospital of Cologne
state: North Rhine-Westphalia
Study officials:
References:
citation: Vehreschild JJ, Ruping MJ, Wisplinghoff H, Farowski F, Steinbach A, Sims R, Stollorz A, Kreuzer KA, Hallek M, Bangard C, Cornely OA. Clinical effectiveness of posaconazole prophylaxis in patients with acute myelogenous leukaemia (AML): a 6 year experience of the Cologne AML cohort. J Antimicrob Chemother. 2010 Jul;65(7):1466-71. doi: 10.1093/jac/dkq121. Epub 2010 Apr 21.
citation: Vehreschild MJ, von Bergwelt-Baildon M, Tran L, Shimabukuro-Vornhagen A, Wisplinghoff H, Bangard C, Cornely OA, Vehreschild JJ. Feasibility and effectiveness of posaconazole prophylaxis in combination with micafungin bridging for patients undergoing allogeneic stem cell transplantation: a 6-yr analysis from the cologne cohort for neutropenic patients. Eur J Haematol. 2014 Nov;93(5):400-6. doi: 10.1111/ejh.12368. Epub 2014 May 26.
citation: Vehreschild MJ, Weitershagen D, Biehl LM, Tacke D, Waldschmidt D, Tox U, Wisplinghoff H, Von Bergwelt-Baildon M, Cornely OA, Vehreschild JJ. Clostridium difficile infection in patients with acute myelogenous leukemia and in patients undergoing allogeneic stem cell transplantation: epidemiology and risk factor analysis. Biol Blood Marrow Transplant. 2014 Jun;20(6):823-8. doi: 10.1016/j.bbmt.2014.02.022. Epub 2014 Mar 6.
Clinical trial NCT04243356: Impact of Intensive Care Unit Nurse Participation in Post - ICU Follow Up Clinic
Official title: Impact of Intensive Care Unit Nurse Participation in Post - ICU (Intensive Care Unit) Follow Up Clinic
Study type: INTERVENTIONAL
Overall status: ENROLLING_BY_INVITATION
Phase: NA
Conditions: Nurse-Patient Relations
Nurse Role
Lead sponsor: University of Michigan
Sponsor class: OTHER
First posted: 2020-01-28
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: The objective of this study is to learn more about the impact of a longitudinal encounter between critical care nurses and former intensive care unit patients. This study will enroll 10 patients that had been admitted in an ICU to meet with a former nurse that had taken care of them in the ICU. The study will enroll 20 nurses that had taken care of these patients in the ICU. The study will randomize 10 nurses to be in the encounter group and 10 nurses to be assigned to the control group. Only nurses assigned to the encounter group will meet with the patients at their post-ICU clinic.


Eligibility criteria: Patients:

Inclusion Criteria:

* Patients that were admitted to the ICU that are appropriate for follow-up.

Nurses:

Inclusion Criteria:

* Registered nurse in an intensive care unit and took care of the enrolled patient

Primary outcomes:
measure: Change in medical ICU nurse fulfillment toward the ICU following an encounter with a former ICU patient in the post-ICU clinic using an adapted Stanford Professional Fulfillment Index
timeFrame: Baseline, at the follow-up ICU clinic visit for the encounter group (approximately 2-4 weeks after discharge)
Secondary outcomes:
measure: Change in medical ICU nurse burnout following an encounter with a former ICU patient in the post-ICU clinic
timeFrame: Baseline, at the follow-up ICU clinic visit for the encounter group (approximately 2-4 weeks after discharge)
Other outcomes:
Locations:
city: Ann Arbor
country: United States
facility: University of Michigan
state: Michigan
Study officials:
affiliation: University of Michigan
name: Jakob McSparron, MD
role: PRINCIPAL_INVESTIGATOR
References: